NCT05113342View on ClinicalTrials.gov

Descartes-25 in Relapsed/Refractory Multiple Myeloma

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 25, 2021

Primary Completion Date

May 9, 2023

Study Completion Date

November 8, 2024

Conditions
Multiple MyelomaRelapse Multiple Myeloma
Interventions
DRUG

Descartes-25

allogeneic Mesenchymal Stem Cell product.

Trial Locations (3)

20817

Center for Cancer and Blood Disorders, Bethesda

71103

Louisiana State University Health Science Center at Shreveport, Shreveport

06200

Saglik Bilimleri Universitesi, Ankara

Sponsors
All Listed Sponsors
lead

Cartesian Therapeutics

INDUSTRY

NCT05113342 - Descartes-25 in Relapsed/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter